Bio-Techne reports Q3 revenue down 2%, GAAP EPS rises to $0.32, driven by strong pharma growth and operational gains.

Bio-Techne Corporation reported a 2% decline in third-quarter revenue to $311.4 million, impacted by timing and prior-year fast-track orders. Despite this, GAAP earnings per share increased to $0.32 from $0.14, supported by strong double-digit growth in large pharma and operational efficiency improvements. The company sees early signs of improving demand as funding and customer purchasing realign, positioning it for long-term value creation. Bio-Techne's diversified portfolio and financial discipline underpin its positive outlook amid mixed market conditions.